WorldHeart/Edwards Pump Up Novacor As Destination Therapy In Europe
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart and marketing partner Edwards Lifesciences will promote the Novacor left ventricular assist device (LVAD) as a destination therapy for heart failure patients in Europe following CE mark approval of a package of device enhancements, expected by the end of May
You may also be interested in...
WorldHeart
Enhanced version of ePTFE inflow conduit for use with the Novacor LVAS left ventricular assist system is reintroduced in EU countries following European approval, the firm announces April 10. WorldHeart withdrew the product in September 2001 to enhance structural integrity following reports of kinking in recovered devices. WorldHeart also has received go-ahead to recommence its halted NICE study of the conduit in the U.S. and plans to seek FDA approval later this year...
Thoratec HeartMate A Good Choice For The Very Sick Despite Risks – Panel
Thoratec's HeartMate VE left-ventricular assist system (LVAS) should be made available to end-stage heart failure patients ineligible for a transplant, even though 94% of patients treated with the LVAS in clinical trials experienced a serious adverse event, FDA's Circulatory System Devices Panel agreed
World Heart Novacor LVAS Transplant Alternative Trial Enrollment At 28
World Heart has enrolled 28 out of 40 patients to be evaluated in the feasibility phase of its INTrEPID trial for its Novacor left ventricular assist system as an alternative-to-transplant destination therapy